GeneDx (NASDAQ:WGS) Upgraded to Strong-Buy at Zacks Research

Zacks Research upgraded shares of GeneDx (NASDAQ:WGS – Free Report) from a hold rating to a strong-buy rating in a report issued on Monday,Zacks reports.

Several other research firms have also commented on WGS. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a report on Monday, November 2nd. BTIG Research reiterated a “buy” rating and set a $85.00 price objective (down from $90.00) on shares of GeneDx in a research note on Tuesday, November 10th. Guggenheim boosted their price objective on GeneDx from $74.00 to $83.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Canaccord Genuity Group boosted their price objective on GeneDx from $75.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Finally, Wall Street Zen upgraded GeneDx from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.14.

Check Out Our Latest Stock Report on WGS

GeneDx Stock Performance

Shares of NASDAQ WGS opened at $47.29 on Monday. The company has a 50 day simple moving average of $72.36 and a two-hundred day simple moving average of $69.72. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of -12.51 and a beta of 2.00. The company has a current ratio of 4.16, a quick ratio of 3.85 and a debt-to-equity ratio of 0.60. GeneDx has a 12 month low of $32.21 and a 12 month high of $170.87.

GeneDx (NASDAQ:WGS – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.07 by $0.21. GeneDx had a negative net margin of 24.10% and a positive return on equity of 1.98%. The firm had revenue of $123.10 million for the quarter, compared to analyst estimates of $122.93 million. During the same quarter in the prior year, the business earned ($0.27) earnings per share. As a group, analysts predict that GeneDx will post -0.41 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Kevin Feeley sold 3,728 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total transaction of $363,890.08. Following the sale, the chief financial officer owned 44,945 shares in the company, valued at approximately $4,387,081.45. This trade represents a 7.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Katherine Stueland sold 10,501 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total transaction of $1,025,002.61. Following the sale, the chief executive officer owned 115,476 shares in the company, valued at approximately $11,271,612.36. This represents a 8.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 19,206 shares of company stock worth $1,808,056 over the last three months. 25.17% of the stock is currently owned by insiders.

Hedge Funds Weigh In On GeneDx

Several institutional investors and hedge funds have recently modified their holdings of the business. First Light Asset Management LLC lifted its position in shares of GeneDx by 222.7% during the 2nd quarter. First Light Asset Management LLC now owns 783,923 shares of the company’s stock valued at $53,816,000 after buying an additional 540,996 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in GeneDx by 108.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 632,413 shares of the company’s stock worth $45,723,000 after acquiring an additional 328,980 shares in the last quarter. William Blair Investment Management LLC increased its holdings in GeneDx by 11.4% in the 3rd quarter. William Blair Investment Management LLC now owns 1,560,247 shares of the company’s stock worth $112,806,000 after acquiring an additional 159,594 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in GeneDx by 143.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 265,791 shares of the company’s stock worth $17,062,000 after acquiring an additional 156,603 shares in the last quarter. Finally, Bank of America Corp DE raised its position in GeneDx by 77.5% during the first quarter. Bank of America Corp DE now owns 234,606 shares of the company’s stock worth $15,066,000 after acquiring an additional 102,456 shares during the period. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

(Get Free Report)

GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results. The company’s testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk. Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.

Further Reading

Analyst Recommendations for GeneDx (NASDAQ:WGS)

Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.